Longevity Questions

Perpetual Prompt ♾️, [08.05.2025 21:15]
661. What is the minimum level of AMPK activation in human tissues required for metformin to sustainably slow down epigenetic aging?
662. Can long-term metformin use in healthy individuals without diabetes cause long-term changes in the expression of genes associated with aging?
663. What is the risk of cognitive decline in elderly patients taking metformin with vitamin B12 deficiency?
664. Does metformin reduce the rate of accumulation of somatic mutations in hematopoietic cells?
665. Can metformin modulate the activity of mobile genetic elements (LINE-1, SINE) involved in aging?
666. In which human tissues is the anti-inflammatory effect of metformin (IL-6, TNF-α, CRP) most pronounced?
667. How does metformin treatment affect regulatory T cells (Tregs) and autoimmune components of age-related degradation?
668. Can metformin restore muscle satellite cell function in the elderly and slow sarcopenia?
669. Is there synergy between metformin and berberine/glucosamine in the context of AMPK activation and mTOR inhibition?
670. How does the geroprotective effect of metformin vary depending on sex, genotype (e.g., SIRT1, FOXO3A), and microbiota?
671. Does chronic stimulation of GLP-1 receptors affect the expression of longevity genes (e.g., Klotho, SIRT1, NRF2)?
672. Can ozempic enhance neurogenesis in the adult hippocampus?
673. How does ozempic affect microcirculation in the capillaries of the brain and retina?
674. Can long-term use of GLP-1 agonists disrupt the composition of the microbiota and thereby limit their geroprotective potential?
675. How pronounced is the reduction in systemic inflammation (CRP, IL-6) with ozempic in people without obesity?
676. Does ozempic suppress the accumulation of lipofuscin and glycated proteins in tissues?
677. Can ozempic prolong lifespan in animal models without obesity or diabetes?
678. Is muscle loss with GLP-1 agonists reversible and can it be prevented with strength training?
679. Can ozempic reduce anxiety and depression through modulation of GLP-1 receptors in the central nervous system?
680. What is the safety of long-term (>10 years) use of ozempic in normal-weight individuals with subclinical aging?
681. Can metformin prevent the diabetogenic effect of statins in the elderly with metabolic syndrome?
682. Is there synergy between statins and ozempic in reducing vascular inflammation (VCAM-1, ICAM-1, E-selectin)?
683. Do statins affect the expression of genes regulating aging (e.g. p16INK4a, p21, LMNB1)?
684. Can the combination of ozempic + statin + metformin effectively prevent vascular calcification in individuals over 60 years of age?
685. How does statin use affect NAD+ levels and sirtuin activity in the elderly?
686. Do PCSK9 inhibitors improve cognitive function with long-term use and is there a relationship with ApoE levels?
687. Can triple therapy (metformin, statins, ozempic) slow the epigenetic clock (Horvath, Hannum)?
688. What changes in the composition of the extracellular matrix are observed with long-term use of this combination?
689. What is the effect on the rate of telomere shortening in patients taking metformin and statins for more than 10 years?
690. To what extent does the combination of ozempic, metformin and statins reduce all-cause mortality in individuals without a diagnosis of diabetes but with high "biological age"?